Bioventus selecteert MEDSERVICE voor distributie in Rusland
HOOFDDORP, Nederland–(BUSINESS WIRE)– Bioventus, leider in ortobiologische oplossingen, heeft MEDSERVICE geselecteerd voor de distributie van DUROLANE ® in Rusland. DUROLANE is een eenmaal te injecteren gewrichtsvloeistof die is gemaakt met het natuurlijke, veilige en bewezen technologische proces NASHA voor de winning van hyaluronzuur (HA). Hyaluronzuur is een molecuul dat in de natuur voorkomt. Het smeert normale gewrichten en zorgt voor schokdemping.
MEDSERVICE levert in Rusland DUROLANE (3ml) voor de symptomatische behandeling van milde tot matige artrose in de knie of heup en DUROLANE SJ (1ml) voor milde tot matige artrose in de enkels, elleboog, pols, vingers en tenen. MEDSERVICE, dat op regionaal en nationaal niveau diensten verleent aan medische instituties, distribueert DUROLANE aan artsen in Moskou en de omliggende regio en alle andere regio’s van Rusland.
Bioventus Selects MEDSERVICE to Distribute DUROLANE® in Russia |
|||||
|
HOOFDDORP, The Netherlands–(BUSINESS WIRE)– Bioventus, a leader in orthobiologic solutions, announced it has selected MEDSERVICE to distribute DUROLANE ® in Russia. DUROLANE is a single-injection joint-fluid based on a natural, safe and proven technology process called NASHA ® which yields stabilized hyaluronic acid (HA). Hyaluronic acid is a naturally occurring molecule that provides the lubrication and cushioning in a normal joint. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170117005896/en/  DUROLANE is a single-injection, hyaluronic acid product used for joint lubrication in the treatment of pain associated with knee osteoarthritis. (Photo: Business Wire)In Russia, MEDSERVICE will offer DUROLANE (3ml) that is indicated for the symptomatic treatment of mild to moderate knee or hip osteoarthritis (OA) and DUROLANE SJ (1ml) associated with mild to moderate osteoarthritis pain in the ankle, elbow, wrist, fingers, and toes. MEDSERVICE, which provides a range of services to medical institutions of regional and federal levels, will distribute DUROLANE to clinicians in the Moscow metropolitan area and throughout all regions of Russia. “We are pleased to make DUROLANE available to patients in Russia again,” said Tony Bihl, CEO, Bioventus. “This market is important to our growth in Europe and our international growth strategy overall as we strive to bring our orthobiologic solutions to patients worldwide.” “MEDSERVICE is off to a great start with DUROLANE in Moscow and we will quickly expand to other cities and regions in Russia this year,” said Andrew McCartney, Managing Director International, for Europe, Middle East and Africa, Bioventus. “The MEDSERVICE team, and the company’s objective to help increase and develop the range of medical products and services provided to patients, is in complete alignment with Bioventus as we work together with the health care community in Russia to help people resume and enjoy active lives.” “We are very excited to work with Bioventus to market DUROLANE in Russia,” said Alexander Yagodin, Managing Director, MEDSERVICE. “This innovative single-injection solution will safely help millions of patients better manage the pain associated with knee osteoarthritis.” About Bioventus Bioventus is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. Bioventus has two product portfolios for orthobiologics, Bioventus Active Healing Therapies and Bioventus Surgical that make it a global leader in active orthopaedic healing. Its EXOGEN ® Ultrasound Bone Healing System is the #1 prescribed bone healing system in the US and is the only FDA-approved bone healing device that uses safe, effective ultrasound to stimulate the body’s natural healing process. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.BioventusGlobal.com and follow the company on Twitter @Bioventusglobal. DUROLANE – Indications DUROLANE (3ml) is indicated for the symptomatic treatment of mild to moderate knee or hip osteoarthritis (OA) and DUROLANE SJ (1ml) associated with mild to moderate osteoarthritis pain in the ankle, elbow, wrist, fingers, and toes. There are no known contraindications. You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children. Risks can include transient pain, swelling and/or stiffness at the injection site. Clinical effectiveness has been demonstrated out to six months but results may vary depending on various patient factors. Bioventus, the Bioventus logo, EXOGEN and DUROLANE are registered trademarks of Bioventus LLC. NASHA is a registered trademark of Galderma S.A. View source version on businesswire.com: http://www.businesswire.com/news/home/20170117005896/en/ Contacts Bioventus |
|||||